{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-003281","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.541389+00:00","generated_at":"2026-06-25T23:01:35.594009+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Odyssey Health reports positive initial Phase I results for concussion drug PRV-002","bullets":["First group of 5 healthy subjects dosed with PRV-002 showed safety and tolerability; no serious adverse events.","Phase I trial ongoing with 48 healthy subjects in single and multi-ascending dose components.","Company plans to present Phase I data to FDA, then initiate Phase II trial in US starting with military.","Concussion affects over 3 million annually in US; no FDA-approved treatment currently exists."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-003281","json":"https://secwatch.observer/filing/0001683168-22-003281.json","markdown":"https://secwatch.observer/filing/0001683168-22-003281.md","text":"https://secwatch.observer/filing/0001683168-22-003281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822003281/0001683168-22-003281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822003281/ody_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:01:35.594009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}